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Strengths and limitations of this study
 ► The inclusion of primary and secondary care data 
allows a wider analysis of disease management.
 ► Patient records included all diagnoses registered 
upon admission, which permits a comorbidity 
analysis.
 ► The burden of prescription drugs could not be eval-
uated via this database.
ABSTRACT
Objectives To investigate the number and characteristics 
of the Spanish population affected by headache disorders 
and the direct medical cost that these patients represent 
for the healthcare system.
Design A retrospective multicentre observational study.
Setting Records from all patients admitted with headache 
in primary and secondary care centres in Spain between 
2011 and 2016 that were registered in a Spanish claims 
database were included in the analysis. Direct medical 
costs were calculated using the standardised average 
expenses of medical procedures determined by the 
Spanish Ministry of Health.
Results Data extraction claimed primary care records 
from 636 722 patients and secondary care records from 
30 077 patients. Women represented 63% and 65% of 
all patients with headache in primary and secondary care 
respectively, with the exception of cluster headaches, a 
group with 60% of male patients. No large shifts were 
observed over time in patients’ profile; contrarily, the 
number of cases per 10 000 patients attended in primary 
care increased 2- folds between 2011 and 2016 for 
migraine and 1.85- folds for other headaches. Migraine 
was the cause for 28% of primary care consultations and 
50% of secondary care admissions, and it was responsible 
for the largest portion of healthcare costs in 2016, a total 
amount of € 7 302 718. The estimated annual direct 
medical cost of headache disorders was € 10 716 086.
Conclusions Migraine was responsible for half of the 
secondary care admissions linked to headache disorders. 
The raise detected in the number of cases registered in 
primary care is likely to impact the direct medical costs 
associated to these disorders causing an increase in 
the total burden they represent for the Spanish National 
Healthcare System.
InTRODuCTIOn
Headache disorders are extremely common, 
experienced by practically everyone at 
some moment in their lives. Annually, the 
percentage of adult population affected with 
headache is around 50% when the multiple 
types of headache are considered.1 Primary 
headache disorders include migraine, 
tension- type headache (TTH), trigeminal 
autonomic cephalalgias (cluster headache 
and hemicrania continua) and others, 
including primary cough headache or those 
associated with sexual activity.2 The most 
common form is TTH, which affects around 
38% of the population.3 Contrarily, trigem-
inal autonomic cephalalgias have a consider-
ably low prevalence. For cluster headache it is 
less than 1%, yet, it is of raising interest due 
to the severity of its symptoms and its impact 
in patients' lives.4
As for migraine, the estimated affected 
population remains around 10% globally, 
with a 12.6% 1 year prevalence in Spain5 6 ; 
indeed, according to the Spanish Statistical 
Office, 5.1% of men and 13.6% of women 
were diagnosed with migraine or frequent 
headache in Spain in 2017.7 Migraine’s socio-
economic and personal impacts determine 
its relevance, as it is considered a major 
cause of disability worldwide.8 The primary 
migraine classification entails migraine with 
aura or without aura; secondary classifica-
tions include chronic migraine, hemiplegic 
migraine and migraine of other origins.3
Altogether, these disorders affect a large 
portion of the population, especially during 
working age, which implicates great public 
health repercussions and socioeconomic 
costs.9 Medical surveys across Europe have 
shown deficiencies in the care that patients 
with persistent headache and migraine 
receive; the portion of patients with 
migraine lacking medical treatment remains 
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significant, and antimigraine treatments are used inade-
quately in an elevated percentage of cases.10 Such inves-
tigations highlight the need to improve health protocols 
for headache symptoms in an effort to reduce their 
personal and economic burden.
The availability of real- world evidence that reflects 
current practice is considered crucial for resource 
allocation decisions in public health and the revi-
sion of the established protocols and guidelines.11 12 
Recent data examining the prevalence and character-
istics of patients with headache and migraine are not 
available; additionally, previous statistics regarding the 
Spanish population were obtained via survey, with an 
assumed analytical error entailed. Hence, the interest 
on obtaining updated epidemiologic data regarding 
these conditions.
The aim of this study was to revise disease incidence 
and the profile of the Spanish population affected by 
headaches and migraine, contributing with novel data 
obtained from a Spanish claims database. A second objec-
tive was to evaluate the direct medical cost that these 
patients represent for the healthcare system, providing a 
basis for the optimisation of resource allocation decisions.
MeThODS
Data extraction
Records of inpatient and outpatient admissions due 
to headache were extracted from a Spanish Ministry of 
Health database that compiles data from private and 
public hospitals, covering around 90% of admissions, 
and primary care centres, covering around 10% of the 
Spanish population, from all Spanish regions.13 14 The 9th 
and 10th revisions of the International Statistical Classifi-
cation of Diseases and Related Health Problems, Clinical 
Modification (ICD9- CM and ICD10- CM) were used to 
claim all admissions registered with a principal diagnosis 
(admission motive) of headache, classified in accordance 
with The International Classification of Headache Disor-
ders, 3rd edition (ICHD-3). Equally, four codes from The 
International Classification of Primary Care (ICPC) were 
used to claim primary care records, corresponding to 
migraine alone, TTH, cluster headache and unspecified 
headaches. Within the database, any healthcare visit that 
is registered in the system is considered an admission. 
Primary care admissions are inherently outpatient and 
specialised care inpatient and outpatient admissions are 
discernible by the length of stay parameter. The records 
extracted corresponded to admissions from the years 
2011 to 2016, the last available data.
Parameters such as health centres and medical history 
identifiers were recoded prior to extraction to maintain 
records anonymised, with no access to identifying infor-
mation, in accordance with the principles of Good Clin-
ical Practice and the Declaration of Helsinki. In such cases 
the Spanish legislation does not require patient consent 
and ethics committee approval.15
Patient and public involvement
Patients were not directly involved in the design, plan-
ning and conception of this study.
Data analysis
The complete admission data was used for both primary 
care and hospitalisation records to evaluate patients’ 
nature of admission and discharge, length of stay, services 
that treated the patients and medical procedures utilised. 
Repeated records corresponding to separated admissions 
were eliminated for the analysis of patients’ character-
istics, relying on the first admission as the index event. 
The direct medical cost was calculated based on the stan-
dardised average expenses of admissions and medical 
procedures determined by the Spanish Ministry of Health, 
available for the year 2016. Cost is presented in total cost 
of all registered admissions and average cost per hospital-
ised patient. These figures include all expenses related to 
the admission: treatment (examination, medication and 
surgery), nutrition, costs associated to personnel, medical 
equipment and resources. Data related to prescription 
medication was not available.
Data presentation is mainly descriptive. The number of 
cases per 10 000 persons attended in primary care was 
calculated from the Ministry of Health database descrip-
tive information.16 Two- sample Z tests were used to test 
for differences in sample proportions, with a p<0.05 
considered statistically significant. Statistical analyses 
were performed using Microsoft Excel Professional Plus 
2010 (Microsoft Corporation, Redmond, Washington, 
USA) and StataSE V.12 for Windows (StataCorp LP. 2011. 




Four unique ICPC codes were used to identify patients 
with unspecified headache, migraine, specified TTH and 
cluster headaches in primary care files, claiming 1 829 
571 records. For hospitalisation records, 97 ICD9 and 
IC10 codes were clustered in 16 sets that identified 32 
517 admissions between 2011 and 2016. Once indexed by 
patients’ first admission, 636 722 single- patient primary 
care files and 30 077 hospitalisation files remained.
The analysis of single- patient data revealed a significant 
sex bias, with a higher percentage of female patients in 
most cases, with the exception of cluster headache. In this 
last group, 61.67% of the patients attended in primary 
care and 59.14% of those attended in hospitals were men 
(table 1). The overall male/female ratio in primary care 
was 37.47% vs 62.53% while in secondary care it was 34.84 
vs 65.15%.
Patients’ age displayed great variability, although the 
mean age for most patients with classifiable syndromes 
remained between 30 and 50 years. Mean patients’ age in 
secondary care slightly increased during the study period.
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Table 1 Number (N) and characteristics of patients diagnosed with headache disorders in primary and secondary care 
centres
N Females % Age (SD)
Primary care
  Unspecified headache 383 464 64.54 39.22 (21.22)
  Migraine 178 081 76.06 40.77 (16.18)
  Tension- type headache 73 408 71.19 45.11 (18.17)
  Cluster headache 1769 38.33 47.60 (15.54)
Secondary care
Primary headaches 29 514 65.32 36.40 (21.72)
  Migraine 14 836 69.58 36.77 (21.55)
   Without aura 1511 73.06 31.95 (17.68)
   With aura 6234 69.60 36.87 (16.59)
   Chronic migraine 480 82.71 41.07 (15.74)
   Hemiplegic migraine 298 62.42 32.25 (18.00)
   Menstrual migraine 30 100.00 32.17 (12.25)
   Persistent aura without cerebral infarction 351 71.79 41.18 (15.72)
   Persistent aura with cerebral infarction 34 70.59 42.47 (15.02)
   Other forms of migraine * 871 59.47 30.92 (18.81)
   Unspecified migraine 5027 69.09 31.63 (19.46)
  Tension- type headache 4348 69.66 44.59 (21.90)
  Trigeminal autonomic cephalalgias 981 47.30 43.85 (18.25)
   Cluster headache 673 40.86 44.03 (17.90)
   Hemicrania continua 308 61.36 45.21 (18.70)
  Other specified headaches† 580 55.69 42.50 (19.65)
  Unspecified headaches 8732 58.63 35.17 (25.52)
Secondary headaches 563 55.95 44.35 (23.06)
  Post- traumatic headache 317 45.11 41.89 (24.16)
  Drug- induced headache 246 69.92 48.63 (20.97)
*With or without mention of status migrainosus.
†Hypnic, primary cough, exercise and stabbing headache, headache associated with sexual activity.
Primary care records allowed an analysis of patients’ 
socioeconomic status. In all cases, around 60% of the 
patients had an income level below € 18 000, while in 
around 20% this ranged between € 18 000 and € 99 999. 
Patients’ employment status displayed a more irregular 
distribution than patients’ income, with a clear dimin-
ished percentage of pensioners (13.82%). The active 
population represented 38.38% of total patients, while 
not active or unemployed patients summed 32.50% of 
the total.
On the other hand, hospital records included a register 
of secondary diagnoses, utilised for the evaluation of 
disease comorbidities, which were evaluated for migraine 
and other headache types separately. In addition, data 
corresponding to male and female patients was anal-
ysed independently (table 2). Overall, hypertension was 
the most common comorbidity, followed by disorders of 
lipoid metabolism as hypertriglyceridemia and hyperlip-
idaemia. Significant differences appeared between men 
and women in the diagnosis of mood disorders (anxiety, 
depressive disorder and dysthymic disorder) and hypo-
thyroidism, primarily found in female patients. The 
frequency of essential hypertension, diabetes, dysthymic 
and depressive disorders and vomiting was consistently 
and significantly higher in patients with migraine vs those 
with other headaches.
The most common comorbidities displayed in table 2 
were analysed in relation with age. Significant differences 
appeared among age groups. Hypertension was found 
in 28.34% of admissions in patients older than 36 years 
of age, while in those under 36 it was found in 1.51% of 
admissions (p<0.001). The same effect was found for the 
disorders of lipoid metabolism, diabetes, hypothyroidism, 
dysthymic and depressive disorders, diagnosed in 16.56%, 
8.75%, 6.06%, 6.71% and 6.14% of admissions in older 
patients, respectively, and 0.81%, 0.24%, 1.50%, 147% 
and 0.85% of admissions in younger patients, respectively 
(p<0.001).
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Table 2 Secondary diagnoses found in patients with migraine and with other headache disorders (excluding migraine)
Females % Males %
Comorbidities Migraine Other headaches Migraine Other headaches
Essential hypertension 19.38*† 11.09* 18.00† 12.48
Disorders of lipoid metabolism 14.61‡ 11.57 15.50‡ 14.12
Tobacco use disorder 9.17†§ 11.73§ 13.71 14.30
Anxiety disorder 8.38‡§ 7.24§ 5.41† 3.77
Diabetes mellitus 6.18†§ 2.19* 7.00† 3.57
Hypothyroidism 5.86§ 5.05§ 1.16 1.13
Dysthymic disorder 5.55†§ 4.26§ 2.53† 1.55
Unspecified asthma 4.26§ 4.40§ 2.76‡ 3.24
Depressive disorder 5.03†§ 3.67§ 2.3 † 1.29
Vomiting 2.84*† 0.73§ 4.04† 1.11
*p<0.05, women versus men.
†p<0.001, migraine versus other headaches.
‡p<0.05, migraine versus other headaches.
§p<0.001, women versus men.
Figure 1 Annual number of cases of headache disorders 
and migraine alone registered per 10 000 primary care 
admissions.
Figure 2 (A) Patients with migraine alone and other 
headaches in primary and secondary care. (B) Percentage of 
patients per headache type in secondary care. CH, cluster 
headache; CM, chronic migraine; MA, migraine with aura; 
MWA, migraine without aura; TTH, tension- type headache.
healthcare management
Total admission data was analysed to obtain information 
on patients’ use of resources and management of the 
disease in both primary and secondary care. Persistent 
headache and migraine were controlled mostly in primary 
care facilities. It was in these centres where the highest 
number of admissions per patient was registered, an 
average of 2.8 for all headaches, 3.2 for migraine alone. 
One admission per patient was registered, on average, in 
specialised centres.
The number of primary care admissions linked to head-
ache disorders in primary care augmented considerably 
over time. The year 2011, 89 958 admissions were regis-
tered for all headache disorders, 26 459 for migraine 
alone; in contrast, the year 2016 those were 451 086 and 
141 252, while the number of new patients remained 
stable. In addition, the number of cases per 10 000 indi-
viduals attended in primary care was calculated, which 
included new patients and successive visits (figure 1). 
The number of cases per 10 000 patients attended in 
primary care increased 2- folds between 2011 and 2016 for 
migraine and 1.85- folds for other headaches (p<0.001, 
2011 vs 2016).
In primary care, patients admitted with migraine 
represented 28.0% of the total, while in secondary care 
the proportion of patients with migraine was 49.7% 
(figure 2A). The scrutiny of specialised care data alone 
showed a predominance of migraine with aura, followed 
by patients with TTH (figure 2B).
The vast majority of hospital admissions for headache 
disorders (90%) were due to emergencies and patients 
stayed hospitalised an average of 4.4 days. Posterior trans-
fers to other facilities were not significant, with 98% of 
the patients discharged to their residences.
The service to treat the most patients was neurology 
(51.85%), followed by paediatrics (22.33%) and internal 
medicine (16.53%). In all cases, procedures related to 
head and brain diagnostic imaging were predominant 
(table 3).
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Computerised axial tomography of head (CT 
scan)
41.86
MRI of the brain 34.11








Routine chest X- ray 6.37
Arteriography of cerebral arteries 5.23
Table 4 Direct medical costs associated to secondary care 




Primary headaches € 2796 € 10 445 179
Migraine € 2736 € 7 302 718
  Without aura € 2752 € 880 585
  With aura € 2674 € 3 123 802
  Chronic migraine € 3132 € 219 246
  Hemiplegic migraine € 2903 € 142 247
  Menstrual migraine € 2019 € 8077
  Persistent migraine aura 
without cerebral infarction
€ 2554 € 125 144
  Persistent migraine aura 
with cerebral infarction
€ 3843 € 30 744
  Other forms of migraine* € 2933 € 225 836
  Unspecified € 2757 € 2 547 038
Tension- type headache € 2803 € 1 981 425
Trigeminal autonomic 
cephalalgias
€ 3534 € 653 752
  Cluster headache € 3712 € 478 789
  Hemicrania continua € 3124 € 174 963
Other specified headaches† € 2941 € 405 820
Unspecified € 2742 € 101 464
Secondary headaches € 2913 € 270 907
Post- traumatic headache € 2695 € 137 452
Drug- induced headache € 3336 € 133 455
*With or without mention of status migrainosus.
†Hypnic, primary cough, exercise and stabbing headache, 
headache associated with sexual activity.
Direct medical cost
The economic costs associated with patients’ use of 
healthcare resources were evaluated for the year 2016 
(table 4). This calculation comprises the cost of secondary 
healthcare associated with a hospitalisation event, and is 
determined by the mean cost of medical procedures and 
hospitalisation days. Headache disorders summed a total 
annual cost of € 10 716 086. Migraine alone represented 
€ 7 302 718 of the total annual cost.
Finally, patients financing scheme was evaluated. As 
expected, the majority of patients were financed by the 
public health system (95.65%).
DISCuSSIOn
Patient profile
According to the Spanish Statistical Office, around 9.4% 
of the Spanish population annually suffers from migraine 
or another frequent headache.7 A national health survey 
reported similar numbers for the year 2017, and esti-
mated that 5.1% men and 13.6% women were affected 
by this condition.17 In the same line are those found in 
the present study, with a male/female ratio of 37.47% to 
62.53% and 34.84% to 65.15% in primary and secondary 
healthcare centres respectively. Equally, surveys have 
shown incidence rates that peak in patients between 35 
and 45 years, which has been confirmed by healthcare 
records,17 with no large shifts observed over time in 
patients’ age and sex distribution.18
The influence of patients’ socioeconomic status was not 
determining in this study; while the majority of patients 
had an income level of under € 18 000, no direct links 
were found with their employment status.
Previous population- based studies have linked head-
aches to several comorbid conditions. Associations have 
been found with illnesses and disorders as hypertension, 
diabetes, hyperlipidaemia, asthma, obesity, hypothy-
roidism and depressive disorders.19–24 Small differences 
were observed between male and female patients, prin-
cipally in the diagnosis of mood disorders and hypothy-
roidism, which appeared to play a more significant role 
in women. These findings were in line with previous esti-
mations in the general population.25 26 Similarly, essential 
hypertension, diabetes, dysthymic and depressive disor-
ders and vomiting were primarily diagnosed in patients 
with migraine versus other headaches. Age was another 
determinant factor in the diagnosis of comorbidities; 
older patients were more likely to be diagnosed with 
hypertension, disorders of lipoid metabolism, diabetes, 
hypothyroidism, dysthymic and depressive disorders, 
while the diagnosis of tobacco use disorder, anxiety 
disorder, asthma and vomiting symptoms did not display 
this correlation.
healthcare management
Patients seeking medical attention for headache disorders 
in Spain were mostly handled in primary care centres. The 
number of patients registered in secondary care facilities 
was only 21% of the total patients registered in primary 
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care, and referral to specialised care and emergency 
visits were in half of the cases due to migraine. Migraines 
with aura were predominant among patients receiving 
hospital inpatient and outpatient care, although aura has 
been found in only 30% of all patients with migraine.27
The prevalence of migraine was estimated to increase 
from 6.5% in 2003 to 9.7% in 2012.28 Herein, primary care 
data inclusion increased a 70% during the study period, 
which explains the increase registered in the number of 
admissions.16 Nonetheless, the number of cases per 10 
000 patients attended in primary care increased signifi-
cantly over the study period, including new patients and 
successive visits. Additionally, previous evaluations suggest 
that neurology consultations, predominant in this study, 
are mainly related to ineffective treatment or increased 
frequency of migraine attacks, which could indicate the 
need to improve treatment protocols.29
Regarding the management of these disorders at the 
hospital level, recommendations call to avoid imaging 
for uncomplicated headache, while previous analysis 
revealed a tendency to perform unnecessary neuroim-
aging tests in patients that fall into that category.30 31 A 
study developed in 2014 in the north of Spain investi-
gated the possible overuse of neuroimaging procedures 
in patients with chronic migraine in a headache clinic.32 
The number of tests performed was considered adequate, 
but CT scans were registered in 76% of admissions and 
MRI in 42%.32 Further research will be necessary to deter-
mine the current application of such recommendations 
in Spain.
Direct medical cost
Updated real- world evidence plays a pivotal role in 
resource allocation decisions in public health.11 12 
Hence, it appears crucial to measure not only patients’ 
use of healthcare resources but the direct medical cost 
associated.
Altogether, headache disorders represent great 
personal and socioeconomic costs, though most evalua-
tions have its focus on migraine. Migraine was identified 
as the sixth leading cause of disability- adjusted life years 
worldwide in people between 25 and 39 years in 2015, 
and those suffering from it are known to have a signifi-
cantly lower health- related quality of life, increased work 
impairment and to require a more intensive healthcare 
resource utilisation.33 34 To quantify the costs of this 
increased use of medical resources, previous studies used 
disease prevalence data as a primary approach. In this 
way, the direct cost of migraine in Spain was estimated to 
sum € 344 million in 2004, including medical admissions 
and prescription medicine.35 Posterior evaluations based 
on surveys measured costs per patient of € 1092 to treat 
episodic migraine in 2012, € 920 when excluding medi-
cation costs,36 a cost significantly lower to that obtained in 
this study, where the costs of specialised admissions alone 
averaged € 2800 per patient in 2016. This cost is tightly 
associated with the number and nature of diagnostic tests; 
however, further research will be necessary to determine 
its utility and whether its use should be adjusted. In addi-
tion, the distinct calculation methods used in both studies 
cannot be ruled out as the origin of cost fluctuation.
This study found similar costs to treat the distinct head-
ache disorders. Earlier calculations assumed a much 
lower annual cost of TTH, around € 300 per person in 
2011.37 In the same revision, the estimated total burden 
of headaches in Spain was over € 22 billion, including 
healthcare, medication costs and indirect costs (lost 
productivity). Herein, secondary care alone summed € 
10 716 086. To add to this calculation is the burden linked 
to work productivity lost, a presumably significant sum, 
and medication.
A number of limitations may have influenced the 
results of this study. Direct medical costs were registered 
leaving out the expenses related to prescription medica-
tion, which need to be considered independently. Further 
research will be necessary to confirm the increasing 
tendency in medical costs and, as a consequence, the 
increasing burden derived from headache disorders.
COnCluSIOnS
Patients receiving specialised care represented around 
21% of those treated in primary care, and as much as 
28% of primary care consultations were due to migraine. 
In addition, this study shows the great importance of 
migraine in secondary care. The increasing number of 
cases of headache disorders attended in primary care 
centres is likely to provoke a raise in the direct medical 
costs associated, increasing the burden they represent for 
the Spanish National Healthcare System.
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